Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (604)	12/3/2008 10:57:17 PM
From: DewDiligence_on_SI	Respond to of 671

If they're to be believed, Rosetta Genomics (ROSG) has a lock on a large number of the known microRNAs. Anyone follow the company? I think idos does.

To: BulbaMan who wrote (604)	12/4/2008 6:55:21 AM
From: idos	Respond to of 671

ROSG does have a very comprehensive microRNA IP portfolio. Company has filed more than 60 patent applications (diagnostics and therapeutic claims, most are composition-of-matter applications) for hundreds of miRNA. To date, only 2 patents were granted: one for viral and the other for human miRNA (miR-492). Both are composition-of-matter patents and are also the first two miRNA patents ever issued by the USPTO. Two more patents were allowed (got positive review). So, I'd say the patent strategy taken towards the USPTO is working. However, the genetic patent arena is relatively young and we don't know yet how courts will treat it.